Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.

Semaglutide reduces vascular resistance and prevents fibrosis in kidneys, supporting kidney function preservation in type 2 diabetes with chronic kidney disease.

• Why it matters: Chronic kidney disease in type 2 diabetes often progresses despite treatment, and understanding how therapies like semaglutide protect kidneys is crucial for improving outcomes.
• What they did: A 52-week randomized trial compared semaglutide 1 mg weekly to placebo in 106 participants, using magnetic resonance imaging, kidney biopsies, and transcriptomics to explore mechanisms of action.
• The result: Semaglutide was linked to decreased renal artery resistance, stabilized tissue diffusion, and molecular changes in endothelial cells, suggesting it prevents fibrosis and enhances vascular health.